Jefferies Group’s CorMedix CRMD Stock Holding History

Jefferies Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,740	Closed	-$139K	–	2575
2019 Q1	$139K	Buy	+14,740	New	+$133K	﹤0.01%	2041

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Jefferies Group's CRMD Position: Q2 2019 in Review

Jefferies Group sold out of CorMedix (CRMD) in Q2 2019, closing a stake of 14,740 shares — an estimated $139K sold.

Jefferies Group first reported a position in CRMD in Q1 2019 and held it in 1 quarter. The position peaked at $139K in Q1 2019. 47 funds tracked by Wall St. Rank hold CRMD as of Q2 2019.

Jefferies Group reported no remaining CorMedix position as of Q2 2019 after selling out during the quarter.
Jefferies Group sold 14,740 CorMedix shares in Q2 2019, an estimated $139K.
Jefferies Group first reported a position in CorMedix in Q1 2019 and held it in 1 quarter.
Jefferies Group's CorMedix position peaked at $139K in Q1 2019.
47 funds tracked by Wall St. Rank held CorMedix as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.